What Percentage of Body Weight Do You Lose on Ozempic?

Last reviewed: June 22, 2026

Last updated: June 22, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has become one of the most studied weight loss medications in recent years. Clinical trials show that patients using semaglutide lose significantly more weight than those on placebo—but the exact percentage varies widely based on dose, duration of treatment, and individual factors. Understanding realistic outcomes helps you set achievable goals and track your progress.

Average Weight Loss Percentage on Semaglutide Therapy

The landmark STEP trials (Semaglutide Treatment Effect in People with obesity) found that patients taking semaglutide at the highest dose (2.4 mg weekly) lost an average of 15.3% of their starting body weight over 68 weeks. Patients on lower doses—1.7 mg and 0.5 mg weekly—lost 11.5% and 5.9% respectively. These figures represent reductions far exceeding what diet and exercise alone typically produce.

Weight loss on semaglutide is not uniform across all patients. Some individuals lose 8-10% in their first 3 months, while others reach 20-25% over a full year of consistent treatment. Factors influencing individual results include baseline metabolic rate, adherence to nutrition changes, physical activity level, sleep quality, and stress management. Genetics also play a significant role—variants in genes like GLP1R and GIPR affect how well your body responds to GLP-1 therapy.

The timeline matters when evaluating semaglutide outcomes. Most patients see noticeable weight loss within 4-8 weeks as appetite suppression increases. The steepest loss typically occurs between months 2-4, then stabilizes at a slower rate by months 5-6. This plateau phase is normal and does not indicate treatment failure—it reflects your body reaching a new baseline weight.

Semaglutide Dosing and Weight Loss: How Dose Affects Results

Semaglutide comes in escalating doses, starting at 0.25 mg weekly and titrating up to a maintenance dose of 2.4 mg weekly. Higher doses correlate with greater average weight loss, but more significant side effects like nausea and vomiting also increase at higher doses. Your optimal dose is the one that produces meaningful weight loss while remaining tolerable—not necessarily the maximum dose available.

Clinical data shows a dose-response relationship: patients on 2.4 mg lose roughly 15% body weight, those on 1.7 mg lose 11.5%, and those on 1.0 mg lose around 9.2%. However, some patients achieve their target weight at lower doses and choose to remain there rather than escalate further. This personalized approach is standard medical practice and focuses on balancing efficacy with tolerability.

PlexusDx compounded semaglutide injections start at just $149 per month, with pricing remaining flat across all dose strengths. Your dose may increase during treatment, but your cost stays the same—a transparent approach that removes financial barriers to finding your effective dose without worrying about escalating expenses.

Individual Factors That Influence Semaglutide Weight Loss Outcomes

Beyond dose, genetics determine a significant portion of semaglutide response variability. Two key genetic variants—GLP1R rs6923761 and GIPR rs1800437—influence how effectively your cells respond to GLP-1 signaling. Individuals with certain variants may experience stronger appetite suppression and greater weight loss, while others may respond more modestly even at higher doses. The Precision Peptide Genetic Test offered by PlexusDx maps these variants along with 47 others across 14 metabolic pathways, providing clarity on your genetic predisposition to GLP-1 response.

Behavioral and lifestyle factors are equally important as biology. Patients who combine semaglutide with consistent calorie awareness, regular physical activity, and adequate sleep typically lose more weight and maintain results longer than those relying on medication alone. Semaglutide suppresses appetite, making it easier to eat less, but it does not eliminate the need for mindful food choices. Protein intake, fiber consumption, and hydration status also correlate with superior outcomes.

Baseline weight and metabolic health affect absolute pounds lost but not necessarily percentage lost. A 300-pound individual losing 15% loses 45 pounds in absolute terms, while a 200-pound individual losing 15% loses 30 pounds—same percentage, different visual impact. Both outcomes represent clinically meaningful weight reduction that improves insulin sensitivity, blood pressure, and cardiovascular risk markers.

Sustaining Weight Loss After Reaching Your Goal on Semaglutide

Weight loss on semaglutide is not temporary—provided you continue the medication and maintain lifestyle habits. Studies tracking patients over 2-3 years show that weight regain occurs primarily in those who discontinue semaglutide without establishing durable eating patterns. If you stop the medication without lifestyle anchoring, your appetite hormones gradually return to baseline and weight often rebounds within 6-12 months.

The goal of semaglutide therapy is not just to lose weight but to establish a sustainable new equilibrium. Many patients reach their target weight—whether that's 10%, 15%, 20%, or 25% below their starting point—and then transition to a maintenance dose. This approach preserves weight loss while often reducing side effects and treatment cost. PlexusDx providers work with you to identify the dose that sustains your results without unnecessary escalation.

Long-term adherence and periodic lifestyle reassessment ensure continued success. Annual check-ins to evaluate hunger levels, energy, metabolic markers, and lifestyle consistency help your provider adjust your semaglutide dose or strategy if needed. Combining medication with ongoing nutrition coaching and exercise habits creates the strongest foundation for durable, meaningful weight loss.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

How much weight will I personally lose on semaglutide?

Average weight loss ranges from 10-15% of body weight, but your individual result depends on your dose, genetics, lifestyle adherence, and metabolic factors. The PlexusDx Precision Peptide Genetic Test can reveal your genetic predisposition to GLP-1 response, helping set realistic expectations tailored to your biology.

How long does it take to see weight loss results on semaglutide?

Most patients notice appetite suppression within 1-2 weeks and measurable weight loss within 4-8 weeks. The rate of loss accelerates between weeks 4-12 as your dose increases, then typically stabilizes by month 4-6 at a slower, steady pace. Full trial results were observed over 68 weeks of treatment.

Does semaglutide work better than other GLP-1 medications for weight loss?

Semaglutide (at its highest 2.4 mg dose) produces comparable weight loss to tirzepatide in head-to-head comparisons, though tirzepatide adds a second hormone pathway (GIP) which may benefit some patients. PlexusDx offers both compounded semaglutide injections starting at $149/month and tirzepatide injections starting at $249/month, allowing personalized selection.

What happens to weight loss if I skip doses or stop semaglutide?

Skipped doses may slow your progress but don't undo prior weight loss if you resume treatment. Discontinuing semaglutide typically leads to gradual weight regain over 6-12 months as appetite hormones normalize. Long-term use combined with sustained lifestyle changes offers the best chance of durable results.

Can the Precision Peptide Genetic Test predict my semaglutide weight loss?

The Precision Peptide Genetic Test ($99 add-on after your first month) identifies variants in GLP1R, GIPR, FTO, MC4R, and 46 other peptide-pathway genes that influence appetite, satiety, and metabolic response. While genetics account for roughly 30-40% of weight loss variance, this insight helps PlexusDx providers optimize your treatment strategy and set evidence-based expectations.

Related Reading

• Can My Dna Tell Me How Do You Lose Weight
• Can A Dna Test Tell Me How Do You Lose Weight
• Can You Get A Dna Test To See How Do You Lose Weight
• Ozempic For Losing Weight

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.